TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29509546
Drug: PARP-1 PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP-1 PET imaging agent
Study: 29509764
Drug: Pharmacological therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapies (aspirin, β-blockers, statins)
Study: 29509992
Drug: Eplerenone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone (25 mg daily for 1 week followed by 50 mg daily for 23 weeks)
Study: 29510735
Drug: Pain-CBT (eight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain-CBT (eight weekly 2-h group sessions with home exercises and readings)
Study: 29510739
Drug: Durvalumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab therapy
Study: 29511132
Drug: OPB-111077, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPB-111077, 250 mg QD (maximum tolerated dose)
Study: 29511132
Drug: OPB-111077, 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPB-111077, 250 mg QD
Study: 29512061
Drug: Avelumab (immunotherapy)
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab (immunotherapy)
Study: 29514175
Drug: Low antituberculosis
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low antituberculosis drug concentrations
Study: 29514256
Drug: Ombrabulin (15.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (15.5 mg/m2), Docetaxel (60 mg/m2), Cisplatin (75 mg/m2)
Study: 29514256
Drug: Ombrabulin (15.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ombrabulin (15.5 mg/m2), Docetaxel (60 mg/m2), Cisplatin (75 mg/m2) with prophylactic G-CSF
Study: 29514256
Drug: Docetaxel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (60 mg/m2) monotherapy
Study: 29514677
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) combined with Task-Oriented Balance Training (TOBT)
Study: 29514815
Drug: Calgranulin-C (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calgranulin-C (0.75 µg/g)
Study: 29514815
Drug: Calprotectin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calprotectin (50 µg/g)
Study: 29514815
Drug: Calprotectin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calprotectin (400 µg/g)
Study: 29515114
Drug: Momelotinib (MMB;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib (MMB; JAK1/2 inhibitor)
Study: 29515514
Drug: Progressive abduction
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive abduction loading therapy with horizontal-plane viscous resistance
Study: 29515514
Drug: Progressive abduction
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive abduction loading therapy without horizontal-plane viscous resistance
Study: 29517567
Drug: Patient e-learning
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient e-learning program, brief advice, educational pamphlet, tobacco quitline referral, letter to the primary care physician, and pharmacotherapy
Study: 29517567
Drug: Amount spent
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amount spent on cigarettes weekly at baseline (per $10 increase)
Study: 29518185
Drug: Microbial diversity
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbial diversity after induction and reinduction phases of chemotherapy
Study: 29518553
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg every 2 weeks) plus Crizotinib (250 mg twice daily)
Study: 29519282
Drug: Manual chest
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual chest compression, electric defibrillation, or epinephrine ≤ 4 mg
Study: 29519282
Drug: Age <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age < 65 years, witnessed CPR, manual chest compression, electric defibrillation, or epinephrine ≤ 4 mg
Study: 29519282
Drug: Total adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total adrenaline ≤ 4 mg
Study: 29519811
Drug: High-sensitivity troponin
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity troponin I (hsTnI) concentrations measured using a single-molecule counting assay (99th percentile, 6 ng/L)
Study: 29519879
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for retinopathy of prematurity (ROP)
Study: 29519879
Drug: Screening of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening of infants with a GA≤34 weeks or a BW<1700 g
Study: 29519879
Drug: Independent risk
Normalized name: Vitamin K-dependent protein S
DrugBank: Protein S human (DB13149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Independent risk factors for severe ROP in infants with a BW≤1500 g
Study: 29519879
Drug: Treatment criteria
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment criteria
Study: 29523153
Drug: Extracorporeal life
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extracorporeal life support (ECLS) treatment
Study: 29523153
Drug: ECLS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECLS treatment
Study: 29523169
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application (App My eReport France®) introduced by a neurologist to report adverse drug reactions (ADR).
Study: 29523171
Drug: Umbilical cord
Normalized name: Sus Scrofa Umbilical Cord
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbilical cord mesenchymal stem cells (UCMSC) intravenous infusions, 7 infusions of 20 × 10^6 cells each.
Study: 29523171
Drug: UCMSC intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: UCMSC intravenous infusions
Study: 29525724
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy (medical treatment and coronary angiogram only if persistent clinical instability)
Study: 29525775
Drug: Individualised, supervised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised, supervised exercise (six weekly sessions)
Study: 29527010
Drug: Veliparib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (200 mg BID) plus FOLFIRI (without 5-fluorouracil bolus)
Study: 29527010
Drug: Veliparib (10-270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib (10-270 mg BID, days 1-5, 15-19) and FOLFIRI (days 1-3, 15-17)
Study: 29527350
Drug: mCME V.2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: mCME V.2.0 intervention (daily SMS quizzes, readings, online CME links, feedback)
Study: 29528048
Drug: Biomarker-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-guided treatment shortening
Study: 29528048
Drug: Standard TB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard TB treatment
Study: 29529091
Drug: Ramadan fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramadan fasting (RF) with aspirin
Study: 29529156
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (≥400 µg/d)
Study: 29530544
Drug: tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tedizolid phosphate 200 mg, once-daily for 7-14 days
Study: 29530544
Drug: linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linezolid 600 mg, twice-daily for 7-14 days
Study: 29530544
Drug: tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tedizolid phosphate 200 mg, once-daily
Study: 29530544
Drug: linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linezolid 600 mg, twice-daily
Study: 29530667
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg intravenously every 2 weeks and axitinib 5 mg orally twice daily
Study: 29530855
Drug: Doripenem administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doripenem administration during dialysis
Study: 29530855
Drug: Post-hemodialysis dosing
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-hemodialysis dosing of Doripenem
Study: 29531651
Drug: Elotuzumab in
Normalized name: elotuzumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elotuzumab in combination with lenalidomide and dexamethasone (ELd)
Study: 29531784
Drug: Verinurad (2.5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad (2.5-20 mg) plus allopurinol (300 mg once daily)
Study: 29531784
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg once daily, 600 mg once daily, or 300 mg twice daily)
Study: 29531839
Drug: None (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: None (control group, did not receive chemotherapy)
Study: 29532104
Drug: GSK3008348, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3008348, single doses of 1-3000 mcg administered by nebulisation
Study: 29532104
Drug: GSK3008348, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3008348, single doses of 300-3000 mcg administered by nebulisation
Study: 29532243
Drug: Multimodal healthy
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal healthy bone behaviors (HBB) education including a healthy bones prescription (BoneRx), face-to-face education, and customized educational materials.
Study: 29533458
Drug: Depatuxizumab mafodotin
Normalized name: Depatuxizumab mafodotin
DrugBank: Depatuxizumab mafodotin (DB11731)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depatuxizumab mafodotin (depatux-m) at a maximum tolerated dose (MTD) of 3.0 mg/kg.
Study: 29533507
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antibiotics during the previous year
Study: 29533531
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for 5 months
Study: 29533710
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (Blood Builder®/Iron Response®) containing 26 mg of iron, vitamin C, folate, and other nutrients, taken once daily for 8 weeks.
Study: 29534721
Drug: CVD 1208S
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 1208S (3 doses, 10 unspecified dosage)
Study: 29535141
Drug: Worsening renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Worsening renal function (WRF) defined as an absolute increase in creatinine of ≥0.3 mg/dL.
Study: 29535545
Drug: Sofosbuvir plus
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir plus oral weight-based ribavirin for 24 weeks
Study: 29535712
Drug: TLR4 agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLR4 agonist glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) with CN54gp140 vaccine, administered intramuscularly three times at 1-month intervals.
Study: 29536342
Drug: Patient-Centered Methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Centered Methadone Treatment (PCM)
Study: 29536342
Drug: Typical Treatment
Normalized name: Atypical neutrophil cytoplasmic antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical Treatment Sessions
Study: 29537444
Drug: 0.3% adapalene
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% adapalene and 2.5% benzoyl peroxide gel plus oral doxycycline 100 mg twice daily
Study: 29537906
Drug: Postoperative concurrent
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative concurrent chemoradiotherapy (CRT), n = 153
Study: 29540222
Drug: Apheresis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apheresis treatment
Study: 29540225
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron and/or folic acid supplementation
Study: 29540225
Drug: Trial provision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial provision of free treatment
Study: 29540234
Drug: Polycap DS®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polycap DS® (containing aspirin 100 mg, atenolol 50 mg, ramipril 5 mg, thiazide 12.5 mg, simvastatin 20 mg) taken as two capsules once daily for 12 months
Study: 29540234
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC) with separate, individual secondary preventive medications prescribed at the physician's discretion
Study: 29540603
Drug: Weekly docetaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly docetaxel, cisplatin, and cetuximab (TPC)
Study: 29541969
Drug: Sustained ventricular
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained ventricular tachyarrhythmia event with appropriate ICD therapy.
Study: 29541969
Drug: All-cause death
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-cause death without preceding sustained ventricular tachyarrhythmia with appropriate ICD therapy.
Study: 29542886
Drug: ICS/LABA combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS/LABA combined therapy
Study: 29543932
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks until disease progression or unacceptable toxic effects
Study: 29544445
Drug: Trastuzumab (Herceptin®)
Normalized name: trastuzumab Injection [Herceptin]
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab (Herceptin®) therapy
Study: 29544454
Drug: Niclosamide 2
Normalized name: niclosamide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niclosamide 2 g orally once a day until disease progression or toxicity
Study: 29545095
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg) every 2 weeks for up to 12 months
Study: 29545772
Drug: Degarelix (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix (0.5 ml bolus injection)
Study: 29545951
Drug: Botox injections
Normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox injections in HFS patients
Study: 29545951
Drug: Healthy volunteers
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers without Botox injections
Study: 29545953
Drug: Selective retina
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective retina therapy (SRT) with real-time feedback-controlled dosimetry
Study: 29546247
Drug: Twice-weekly in-person
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly in-person and telephone-based guidance on calorie-restricted diets and aerobic exercise
Study: 29548561
Drug: Three-dimensional conformal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dimensional conformal radiation therapy (3-DCRT)
Study: 29548934
Drug: 1.8 mg
Normalized name: menthol 1.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg liraglutide once daily
Study: 29548934
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg glimepiride together with 1 g metformin twice daily
Study: 29549175
Drug: Abatacept (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (10 mg/kg, expansion cohort)
Study: 29549175
Drug: Abatacept (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abatacept (all doses)
Study: 29549598
Drug: Adapalene 0.3%
Normalized name: ADAPALENE 0.3% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.3% gel, applied once daily for the first 4 weeks and twice daily for the following 20 weeks.
Study: 29550382
Drug: Voxtalisib 50
Normalized name: Voxtalisib
DrugBank: Voxtalisib (DB12400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxtalisib 50 mg orally twice daily in 28-day continuous dosing cycles until progression or unacceptable toxicity
Study: 29550382
Drug: Voxtalisib 50
Normalized name: Voxtalisib
DrugBank: Voxtalisib (DB12400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxtalisib 50 mg orally twice daily
Study: 29551225
Drug: Flubio® (Influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flubio® (Influenza HA Trivalent) vaccine, administered in 1 or 2 doses with a 28-day interval.
Study: 29551225
Drug: Flubio® (Influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flubio® (Influenza HA Trivalent) vaccine
Study: 29551338
Drug: Sirolimus (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (2 mg per day, adjusted to maintain a therapeutic range of 6-15 ng/mL) for 12 months
Study: 29551401
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 25-s time delay and $0.25 discount
Study: 29551401
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 25-s time delay and $0.25 tax
Study: 29551775
Drug: Ilorasertib 40-340
Normalized name: Ilorasertib
DrugBank: Ilorasertib (DB11694)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilorasertib 40-340 mg orally twice daily (Arm II)
Study: 29551775
Drug: Ilorasertib 10-180
Normalized name: Ilorasertib
DrugBank: Ilorasertib (DB11694)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilorasertib 10-180 mg orally once daily (Arm I)
Study: 29551775
Drug: Ilorasertib 8-32
Normalized name: Ilorasertib
DrugBank: Ilorasertib (DB11694)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilorasertib 8-32 mg intravenously once daily (Arm III)
Study: 29552014
Drug: Intralesional (IL)
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional (IL) treatment with ipilimumab
Study: 29552321
Drug: Vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg twice daily plus fotemustine 100 mg/m2 intravenously every three weeks
Study: 29552321
Drug: Vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg twice daily plus fotemustine
Study: 29552356
Drug: Prolonged-release fampridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release fampridine (PRF) 10 mg BID
Study: 29556418
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg every 2 weeks plus csDMARDs
Study: 29558281
Drug: Veliparib with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib with concurrent radiotherapy (RT) to the chest wall and regional lymph nodes (50 Gy plus a 10-Gy boost)
Study: 29560743
Drug: Liletta (levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liletta (levonorgestrel 52 mg IUS)
Study: 29561066
Drug: IdeS (imlifidase)
Normalized name: IDE-CEL
DrugBank: Imlifidase (DB15258)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: IdeS (imlifidase) 0.12 mg/kg body weight ×2
Study: 29561066
Drug: IdeS (imlifidase)
Normalized name: IDE-CEL
DrugBank: Imlifidase (DB15258)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: IdeS (imlifidase) 0.25 mg/kg ×1
Study: 29561066
Drug: IdeS (imlifidase)
Normalized name: IDE-CEL
DrugBank: Imlifidase (DB15258)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: IdeS (imlifidase) 0.25 mg/kg ×2
Study: 29561219
Drug: Acute reperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute reperfusion therapies including thrombectomy and thrombolysis in the acute phase
Study: 29561296
Drug: Talimogene laherparepvec
Normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Talimogene laherparepvec (≤4 ml 10 PFU/ml; administered on day 1 and every 2 weeks thereafter)
Study: 29562855
Drug: RectroNectin-activated cytokine-induced
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RectroNectin-activated cytokine-induced killer (R-CIK) cell immunotherapy
Study: 29563871
Drug: Naltrexone and
Normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone and Bupropion combination treatment
Study: 29564045
Drug: Prolonged-release oxycodone/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release oxycodone/naloxone at a starting dose of 10/5 mg/day (maximum 80/40 mg/day) for 8 weeks
Study: 29564045
Drug: Prolonged-release oxycodone/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release oxycodone/naloxone
Study: 29565424
Drug: 4,000 L rhGAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,000 L rhGAA
Study: 29566106
Drug: Avelumab, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab, 10 mg/kg, by 1-hour intravenous infusion every 2 weeks until disease progression or unacceptable toxic effects.
Study: 29566186
Drug: Red and
Normalized name: ferric oxide (red and/or yellow)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red and processed meat intake (10 g/d)
Study: 29566186
Drug: Cereal intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal intake (50 g/d)
Study: 29566186
Drug: Dietary fiber
Normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fiber intake (10 g/d)
Study: 29566190
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake from dairy products (per 5 g/d)
Study: 29566190
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake from meat and fish (per 2 g/d)
Study: 29566246
Drug: Glecaprevir/pibrentasvir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/pibrentasvir (300 mg/120 mg) for 8 weeks in noncirrhotic patients and 12 weeks in cirrhotic patients.
Study: 29566656
Drug: blended cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: blended cognitive behavioral therapy (b-CBT) consisting of three face-to-face sessions and eight online sessions